Stivarga Real Life Evidence in Hungary

Bayer logo

Bayer

Status

Completed

Conditions

Colorectal Neoplasms

Treatments

Drug: Regorafenib (Stivarga, BAY73-4506)

Study type

Observational

Funder types

Industry

Identifiers

NCT02656524
18686

Details and patient eligibility

About

The study aims to evaluate use of regorafenib in clinical practice in Hungary. The study should provide information about clinical characteristics of Hungarian regorafenib patients as well as information about safety and efficacy of regorafenib in Hungarian patients with metastatic colorectal cancer. This much needed data is required by the National Health Insurance Fund in order to accept regorafenib into the regular reimbursement system. This study is proposed to be based on patient data from the Hungarian National Health Insurance Fund's Database. Data to be analyzed includes patient demography and baseline tumor characteristics, overall survival, time to treatment failure, duration of treatment, average dose and dose modifications, and adverse events. Further, treatment costs will be estimated.

Enrollment

400 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Using the National Health Insurance Database, patients will be included in this retrospective data analysis if they had at least one dose of regorafenib treatment cycle (=28 days).

Exclusion criteria

  • Not applicable

Trial design

400 participants in 1 patient group

Cohort1/Regorafenib
Description:
All patients with at least 1 treatment with regorafenib
Treatment:
Drug: Regorafenib (Stivarga, BAY73-4506)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems